RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. (IST:RTALB)
Turkey · Delayed Price · Currency is TRY 4.120
+0.070 (1.73%)
At close: Feb 9, 2026
IST:RTALB Income Statement
Financials in millions TRY. Fiscal year is January - December.
Millions TRY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 168.47 | 158.59 | 138.51 | 191.3 | 384.34 | 230.44 | |
Revenue Growth (YoY) | -15.67% | 14.50% | -27.59% | -50.23% | 66.79% | 1274.46% |
Cost of Revenue | 108.12 | 117.61 | 112.71 | 126.73 | 228.46 | 144.16 |
Gross Profit | 60.35 | 40.98 | 25.8 | 64.57 | 155.88 | 86.29 |
Selling, General & Admin | 45.91 | 37.92 | 44.92 | 54.89 | 40.54 | 30.82 |
Research & Development | 26.24 | 22.19 | 21.46 | 14.23 | 16.6 | 5.26 |
Other Operating Expenses | 8.75 | 23.08 | 9.28 | 11.05 | 3.95 | -2.27 |
Operating Expenses | 80.89 | 83.19 | 75.66 | 80.17 | 61.09 | 33.8 |
Operating Income | -20.54 | -42.2 | -49.86 | -15.6 | 94.79 | 52.48 |
Interest Expense | -70.55 | -78 | -29.44 | -32.18 | -19.73 | -6.03 |
Interest & Investment Income | 136.51 | 73.99 | 126.42 | 76.02 | 19.58 | 12.31 |
Earnings From Equity Investments | 526.86 | 119.52 | -61.23 | 280.78 | 46.86 | 31.46 |
Currency Exchange Gain (Loss) | -2.32 | 7.37 | 46.38 | 79.98 | 6.88 | 1.39 |
Other Non Operating Income (Expenses) | 56.01 | -81.94 | -133.37 | -213.34 | -0.18 | -0.26 |
EBT Excluding Unusual Items | 625.96 | -1.26 | -101.1 | 175.66 | 148.21 | 91.35 |
Gain (Loss) on Sale of Investments | -11.67 | -50.4 | -3.66 | -2.79 | -0.85 | -3.36 |
Pretax Income | 614.29 | -51.66 | -104.76 | 172.87 | 147.36 | 87.99 |
Income Tax Expense | 198.46 | -103.9 | -1.6 | 36.55 | 20.06 | 9.59 |
Earnings From Continuing Operations | 415.84 | 52.23 | -103.16 | 136.32 | 127.3 | 78.4 |
Minority Interest in Earnings | - | - | - | -155.95 | -12.83 | -17.46 |
Net Income | 415.84 | 52.23 | -103.16 | -19.62 | 114.47 | 60.93 |
Net Income to Common | 415.84 | 52.23 | -103.16 | -19.62 | 114.47 | 60.93 |
Net Income Growth | - | - | - | - | 87.87% | 1277.70% |
Shares Outstanding (Basic) | 500 | 500 | 500 | 500 | 500 | 477 |
Shares Outstanding (Diluted) | 500 | 500 | 500 | 500 | 500 | 477 |
Shares Change (YoY) | -0.10% | - | - | - | 4.81% | 43.63% |
EPS (Basic) | 0.83 | 0.10 | -0.21 | -0.04 | 0.23 | 0.13 |
EPS (Diluted) | 0.83 | 0.10 | -0.21 | -0.04 | 0.23 | 0.13 |
EPS Growth | - | - | - | - | 79.25% | 859.24% |
Free Cash Flow | 174.63 | -180.9 | 23.93 | -0.77 | 47.35 | -6.59 |
Free Cash Flow Per Share | 0.35 | -0.36 | 0.05 | -0.00 | 0.10 | -0.01 |
Gross Margin | 35.83% | 25.84% | 18.63% | 33.76% | 40.56% | 37.44% |
Operating Margin | -12.19% | -26.61% | -36.00% | -8.15% | 24.66% | 22.77% |
Profit Margin | 246.83% | 32.94% | -74.48% | -10.26% | 29.78% | 26.44% |
Free Cash Flow Margin | 103.66% | -114.07% | 17.28% | -0.40% | 12.32% | -2.86% |
EBITDA | -1.66 | -25.43 | -33.85 | 6.66 | 98.74 | 54.28 |
EBITDA Margin | -0.99% | -16.04% | -24.44% | 3.48% | 25.69% | 23.56% |
D&A For EBITDA | 18.88 | 16.77 | 16.01 | 22.26 | 3.95 | 1.8 |
EBIT | -20.54 | -42.2 | -49.86 | -15.6 | 94.79 | 52.48 |
EBIT Margin | -12.19% | -26.61% | -36.00% | -8.15% | 24.66% | 22.77% |
Effective Tax Rate | 32.31% | - | - | 21.14% | 13.61% | 10.90% |
Advertising Expenses | - | - | 0.02 | 0.02 | 1.18 | 0.27 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.